Biogen Stock Forecast
NASDAQ: BIIBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 3:00 PM ET
BIIB analyst consensus
Consensus (35 analysts)
buy
Avg. price target
$238.18+5.74%
- Strong buy 3
- Buy 19
- Hold 12
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 35 Wall Street analysts covering Biogen (2026-10-07), 22 rate the stock a buy or strong buy, 12 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $238.18, with a high estimate of $300.00 and a low estimate of $175.00. The average target implies upside of 5.7% from the current price of $225.26.
The spread between the highest and lowest targets is 71.4%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for BIIB.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 9% |
| Buy | 19 | 54% |
| Hold | 12 | 34% |
| Sell | 1 | 3% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $175.00 | -22.31% |
| Average target | $238.18 | +5.74% |
| High target | $300.00 | +33.18% |